Phaseline

Targets › SEMA4D

SEMA4D (Semaphorin-4D): drug programs, companies and trials

1 program from 1 company in 3 trials: 3 Phase 1; Oncology; next expected readout Dec 2028.

Cell surface receptor for PLXNB1 and PLXNB2 that plays an important role in cell-cell signaling. Regulates GABAergic synapse development (By similarity). (UniProt, Q92854)

Open in Phaseline: the race on SEMA4D, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
VaccinexPepinemab
Semaphorin-4D inhibitor
SEMA4DPhase 1Metastatic Pancreatic Adenocarcinoma; Squamous Cell Carcinoma of the Head and Neck; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Dec 2028

Conditions

Metastatic Pancreatic Adenocarcinoma (1) Squamous Cell Carcinoma of the Head and Neck (1) Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 (1)

Modalities

antibody (1)

Companies

Vaccinex (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.